Amgen’s Neulasta Ad Indirectly Targeting Biosimilars Draws US FDA Rebuke

 
• By Brenda Sandburg
  
FDA objects to Amgen's Neulasta promotion • Source: illustration/FDA
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Marketing & Advertising

More from Compliance